SCHEMBL801207

SCHEMBL801207

CC(=O)/C(C#N)=C/c1ccc(O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.71
KDM4E B2RXH2 3/20 0.71
CYP3A4 P08684 2/20 0.71
HPGD P15428 2/20 0.71
CISD1 Q9NZ45 2/20 0.71
SLC16A3 O15427 1/20 0.71
SLC16A1 P53985 1/20 0.71
GPR35 Q9HC97 1/20 0.71
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
EGFR P00533 2/20 0.57
CYP1A2 P05177 1/20 0.57
PKM P14618 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
BLM P54132 1/20 0.57
PMP22 Q01453 1/20 0.57
HIF1A Q16665 1/20 0.57
HSD17B10 Q99714 1/20 0.57
THRB P10828 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21430785 0.85 EGFR (0.54) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL13060204 0.84 ALDH1A1 (0.74) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL7903277 0.84 KDM4E (0.62) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL230147 0.84 KDM4E (0.62) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL230148 0.84 KDM4E (0.62) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL13164595 0.83 MCL1 (0.68) ALDH1A1KDM4ECYP3A4HPGDCISD1
Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26825 0.83 KDM4E (1.00) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL6344579 0.83 MCL1 (0.68) ALDH1A1KDM4ECYP3A4HPGDCISD1
SCHEMBL6344582 0.83 MCL1 (0.68) ALDH1A1KDM4ECYP3A4HPGDCISD1
Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26826 0.83 KDM4E (1.00) ALDH1A1KDM4ECYP3A4HPGDCISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210855-A1 USE OF MCT1 INHIBITORS TO ENHANCE INSULIN SENSITIVITY H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-06 US disclosed
US-9958449-B2 Method for enzyme-mediated signal amplification DAKO DENMARK A/S (DK) 2018-05-01 US disclosed
US-20160274122-A1 NEW METHOD FOR ENZYME-MEDIATED SIGNAL AMPLIFICATION DAKO DENMARK APS (DK) 2016-09-22 US disclosed
US-9366675-B2 Method for enzyme-mediated signal amplification DAKO DENMARK A/S (DK) 2016-06-14 US disclosed
WO-2015102418-A2 PEPTIDOMIMETIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR TREATING ALLERGIC DISORDERS INCLUDING SAME 이화여자대학교 산학협력단 2015-07-09 WO disclosed
US-9012838-B2 Covalently functionalized nanodiamond-based MALDI matrices and methods of use thereof UNIVERSITY OF SASKATCHEWAN (CA) 2015-04-21 US disclosed
US-20140312218-A1 COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF UNIVERSITY OF SASKATCHEWAN (CA) 2014-10-23 US disclosed
US-20140162245-A1 NEW METHOD FOR ENZYME-MEDIATED SIGNAL AMPLIFICATION DAKO DENMARK APS (DK) 2014-06-12 US disclosed
US-8168372-B2 semiconductors; microelectronic structures with nanosized features; acetylacetone complexes of titanium or zirconium; ethyl 2-cyano-3-(4-hydroxy-phenyl)-acrylate; crosslinker; solvent BREWER SCIENCE INC. (US) 2012-05-01 US disclosed
US-20120070856-A1 CROSS-LINKING AGENTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 2012-03-22 US disclosed
EP-2226314-A1 Cross-linking agents CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) 2010-09-08 EP disclosed
US-20080076064-A1 METHOD OF CREATING PHOTOLITHOGRAPHIC STRUCTURES WITH DEVELOPER-TRIMMED HARD MASK BREWER SCIENCE INC. 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140312218-A1 COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF ITGA2B, MMP2, ITGAV ALDH1A1 1988/4885KDM4E 2997/4885CYP3A4 3354/4885
US-20230210855-A1 USE OF MCT1 INHIBITORS TO ENHANCE INSULIN SENSITIVITY SLC2A1, SLC2A2, SLC16A1 ALDH1A1 1679/4885KDM4E 1345/4885CYP3A4 2605/4885
US-20120070856-A1 CROSS-LINKING AGENTS ORC3, TXN, PROC ALDH1A1 2055/4885KDM4E 3357/4885CYP3A4 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.